What is Methocarbamol?
Methocarbamol is a centrally acting skeletal muscle relaxant and sedative available in both oral and intravenous formulations, used as an adjunct to rest and physical therapy for acute, painful musculoskeletal conditions. 1
Mechanism of Action
The precise mechanism of action remains unclear, but methocarbamol does not directly relax tense skeletal muscles 2. Its therapeutic effects are likely related to its sedative properties and central nervous system (CNS) depressant activity 1.
Chemical Structure
Methocarbamol is a carbamate derivative of guaifenesin with the chemical name 3-(2-methoxyphenoxy)-1,2-propanediol 1-carbamate (molecular formula C₁₁H₁₅NO₅, molecular weight 241.24) 1. It appears as a white powder, sparingly soluble in water and chloroform 1.
Formulations and Dosing
- Oral tablets: Available in 500 mg and 750 mg strengths 1
- Intravenous: Contains polyethylene glycol (PEG) 300 and propylene glycol as excipients 3
Adverse Effects Profile
Central Nervous System
- Drowsiness and dizziness are the most common side effects 2
- Acts as a CNS depressant with sedative properties 1
Cardiovascular
- Bradycardia and hypotension can occur, particularly with IV administration 2
Drug Interactions
- Critical interaction with alcohol: Fatal CNS depression can occur when combined with ethanol due to additive sedative-hypnotic effects 4
- Interferes with pyridostigmine bromide: Should not be used in patients with myasthenia gravis 2
Special Populations and Contraindications
Renal and Hepatic Impairment
Methocarbamol elimination is significantly impaired in patients with liver and kidney disease 2. Dose adjustments or alternative agents should be considered in these populations.
Absolute Contraindication
- Myasthenia gravis due to interference with pyridostigmine bromide effects 2
Perioperative Management
According to the 2021 SPAQI consensus guidelines, methocarbamol should be held on the day of surgical procedures 2. Despite one single-center study showing potential benefits in postoperative opioid consumption and recovery metrics after arthroplasty 2, the consensus recommendation prioritizes avoiding potential cardiovascular complications (bradycardia, hypotension) during anesthesia.
Abuse Potential
Unlike other muscle relaxants such as carisoprodol, methocarbamol demonstrates low likelihood of abuse based on behavioral pharmacology studies showing it does not maintain self-administration behavior and lacks discriminative stimulus effects similar to barbiturates or benzodiazepines 5.
Clinical Considerations
IV Formulation Concerns
The IV formulation contains PEG 300, which has been implicated in metabolic acidosis and nephrotoxicity, though evidence remains controversial 6. To mitigate potential risks, IV methocarbamol is typically limited to 72 consecutive hours followed by a 48-hour drug-free interval, though recent data suggest this may be overly cautious 3.
Anticholinergic Effects
Recent ICU data show anticholinergic adverse effects occur in approximately 10.8% of patients receiving methocarbamol, though these rarely lead to medication discontinuation 7.
Analytical Challenges
Methocarbamol presents significant analytical challenges due to low UV absorptivity, rapid metabolism, and pronounced pH-dependent instability 8, which can complicate therapeutic drug monitoring when needed.